Company Information

  

Address: 3535 GENERAL ATOMICS COURT
SUITE 200 
City: SAN DIEGO 
State: CA 
Zip Code: 92121 
Telephone: 858.875.1803 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

We are a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. We are developing first-in-class cell therapy product candidates based on a simple notion: we believe that better cell therapies start with better cells. To create better cell therapies, we use an approach that we generally refer to as cell programming. For certain of our product candidates, we use pharmacologic modulators, such as small molecules, to enhance the biological properties and therapeutic function of cells ex vivo before our product candidates are administered to a patient. In other cases, we use human induced pluripotent stem cells (iPSCs), generate a clonal master iPSC line having preferred biological properties, and direct the fate of the clonal master iPSC line to create our cell therapy product candidate.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2018-1.18NAN/E
03/2018-1.05NAN/E
12/2017-1.02NAN/E
09/2017-0.94NAN/E
06/2017-0.95NAN/E
03/2017-1.00NAN/E
12/2016-1.05NAN/E
09/2016-1.11NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.15Total Liab/Total Assets0.27
Net Inc/Total Assets-0.41Total Liab/Inv Cap0.30
Net Inc/Inv Cap-0.46Total Liab/Comm Equity0.09
Pretax Inc/Net Sales-10.46Interest Coverage Ratio-32.87
Net Inc/Net Sales-10.46Curr Debt/EquityNA
Cash Flow/Net Sales-8.99LTD/Equity0.19
SG&A/NetSales2.89Total Debt/Equity0.19
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio9.29
Inventory TurnoverNACurrent Ratio9.29
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work Cap0.04Inv/Curr AssetsNA
Net Sales/PP&E1.61  

Income Statement (Millions)

  6/30/2018 3/31/2018 12/31/2017 9/30/2017
Total Revenues(Net Sales) 1.03 1.03 1.03 1.03
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 3.82 3.60 3.38 2.79
Operating Income -19.61 -14.05 -12.24 -10.34
Interest Exp 0.43 0.41 0.41 0.38
Pretax Income -19.65 -14.14 -12.50 -10.68
Other Income 0.38 0.33 0.16 0.03
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -19.65 -14.14 -12.50 -10.68

Balance Sheet (Millions)

Assets 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Cash & Short Term Investments 78.02 88.63 100.95 69.21
Receivables - Total NA 0.50 NA NA
Inventories - Total NA NA NA NA
Total Current Assets 80.03 90.63 102.60 70.04
Net Property, Plant & Equipment 2.89 2.65 2.55 2.49
Total Assets 83.16 93.42 105.29 72.68
Liabilities        
Accounts Payable 11.89 9.60 8.93 7.61
Debt in Current Liabilities 2.01 0.76 0.00 0.00
Total Current Liabilities 16.27 12.59 11.05 9.72
Long-Term Debt 12.84 14.07 14.81 14.79
Total Liabilities 31.33 28.43 28.10 26.93
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.05 0.05 0.05 0.04
Retained Earnings -252.59 -232.93 -218.80 -206.30
Treasury Stock NA NA NA NA
Total Stockholders' Equity 51.83 65.00 77.19 45.75
Total Liabilities and Stockholders' Equity 83.16 93.42 105.29 72.68

Cash Flow Summary (Millions)

Categories 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Net Cash Provided by Operating Activities -11.52 -12.55 -10.72 -9.86
Net Cash Provided by Investing Activities 13.72 -43.84 13.20 13.64
Net Cash Provided by Financing Activities 1.16 0.36 43.24 8.39

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.97-20.89-3.54
12/20140.00-25.88-1.27
12/20152.43-29.99-1.18
12/20164.40-33.46-1.05
12/20174.11-42.95-1.02
Growth Rates43.40----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/1812243,35081.15




Report Date : 9/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.